EPR Tumor Oximetry With CE India Ink
Tumor Oximetry Using Electron Paramagnetic Resonance (EPR) With India Ink (Using Carbon Particulates From Carlo Erba [CE])
Sponsor: National Cancer Institute (NCI)
Terminated
The research team is exploring device optimization
Other terminated trials from National Cancer Institute (NCI)
This observational or N/A phase trial investigates Breast Neoplasm and Carcinoma, Basal Cell and is currently terminated or withdrawn. National Cancer Institute (NCI) leads this study, which shows 12 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
Dec 2021 — Jul 2024 [monthly]
Terminated
-
Jan 2021 — Dec 2021 [monthly]
Terminated
-
Nov 2020 — Jan 2021 [monthly]
Terminated
▶ Show 7 earlier versions
-
Jan 2020 — Nov 2020 [monthly]
Terminated
Status: Suspended → Terminated
-
Aug 2019 — Jan 2020 [monthly]
Suspended
Status: Recruiting → Suspended
-
Mar 2019 — Aug 2019 [monthly]
Recruiting
-
Jun 2018 — Mar 2019 [monthly]
Recruiting
-
May 2018 — Jun 2018 [monthly]
Recruiting
-
Apr 2018 — May 2018 [monthly]
Recruiting
Phase: NA → None
-
Nov 2017 — Apr 2018 [monthly]
Recruiting NA
First recorded
Aug 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
- Philip Schaner
For direct contact, visit the study record on ClinicalTrials.gov .